Living with Diabetes? Check out our site for you

Healthcare professional? This is your dedicated site.

CGM Funding is here

CGM FUNDING
IS HERE

CGM funding is here

CGM FUNDING
IS HERE

CGM FUNDING IS HERE

Prime Minister Malcolm Turnbull has fulfilled the Coalition’s pledge to spend $54 million subsidising continuous glucose monitoring [CGM] for eligible Australians with Type 1 diabetes. The promise, originally made on 15 May 2016, will be fulfilled from 1 April 2017 for Australians under the age of 21 who meet specific criteria.

This decision reflects years of effort by members of the diabetes community. We congratulate everyone involved.

Funding will apply to Medtronic CGM products used with a Medtronic Insulin Pump or standalone CGM with the new Guardian ™ Connect

This is a positive first step in improving diabetes management within our community. However, we realise that it does not provide CGM to everyone and that it should be a continued priority of our community to improve access to all who may benefit. For people who are not eligible, Medtronic will continue to offer CGM subscription packages.

The eligibility criteria for the ‘CGM Initiative’ announced is available from the NDSS and listed below.

Category (A) Category (B)

Children 10 years of age and younger with type 1 diabetes will be eligible for subsidised access to CGM with alarms if they fulfil all of the following criteria:

  • the child is aged up to ten (10) years of age with type 1 diabetes; and
  • the child is expected to benefit clinically from the use of CGM; and
  • the family/carer has the willingness and capability to use CGM; and
  • the family/carer has the commitment to actively participate in a diabetes management plan which incorporates CGM.

Those children who turn 11 and have been accessing CGM products through the initiative will continue to have subsidised access. They will not need to be reassessed under Category B.

 

Children and young people with type 1 diabetes aged from 11 years to less than 21 years will be eligible for subsidised access to CGM with alarms if they fulfil all of the following criteria:

  • the individual is expected to benefit clinically from the use of CGM: and
  • the individual or family/carer has the willingness and capability to use CGM; and
  • the individual or family/carer has the commitment to actively participate in a diabetes management plan which incorporates CGM.

and they fulfil one or more of the following criteria:

  • frequent significant hypoglycaemia - more than one episode a year of significant hypoglycaemia requiring external, third party assistance; and/or
  • impaired awareness of hypoglycaemia; and/or
  • inability to recognise, or communicate about, symptoms of hypoglycaemia; and/or
  • significant fear of hypoglycaemia for the child/young person or a family member/carer which is seriously affecting the health and wellbeing of those persons or contributing to hyperglycaemia as a reaction to this fear.

For young people in either category, subsidised access to CGM products will cease once they reach 21 years of age.

 

WHICH MEDTRONIC PRODUCTS ARE COVERED?

Medtronic have four products available through the CGM Initiative; the Enlite™ Sensor, Guardian™ 2 Link, MiniLink transmitter, Guardian Connect™ CGM. CGM technology enables a user to monitor glucose levels 24 hours a day through a sensor.

 

The varieties of Medtronic CGM in Australia

   

Guardian 2 Link CGM

MiniLink CGM

Guardian Connect

Pump / Phone Compatibility

MiniMed 640G Pump

Paradigm Veo,  Paradigm Real-Time Insulin Pumps

Apple iOS
(iPhone, iPod Touch, iPad)

Real-time values on receiver

Yes

Yes

Yes

Share reports with healthcare professionals

If HCP links CareLink Professional to CareLink Personal, they can access up-to-date reports following patient upload

If HCP links CareLink Professional to CareLink Personal, they can access up-to-date reports following patient upload

If HCP links CareLink Professional to CareLink Personal, they can access up-to-date reports daily

Transmitter Memory Storage

10 hours

40 mins

14 days

Sensor

Enlite

Enlite

Enlite

Alerts

Yes

Yes

Yes

Remote Partner Notification

No

No

Yes, up to 5 registered Care Partners AND optional SMS

 

HOW PATIENTS CAN BENEFIT FROM MEDTRONIC CGM

CGM measures and indicates glucose levels continuously [24/7] to assist in monitoring. It can be used by type 1 and type 2 diabetes patients who would like better glucose control to improve the health and quality of their lives – and can help to take the guesswork out of glucose monitoring.

There are two ways patients can benefit from Medtronic CGM:

  • With an insulin pump. With CGM and the Medtronic Veo or MiniMed 640G Insulin Pump, insulin delivery can be automatically stopped to reduce the occurrence or severity of hypoglycaemia1,2. Patients have the ability to set alerts to warn about highs or lows, and will see the full picture of glucose levels 24/7 on the device.
  • Without an insulin pump. Guardian™ Connect CGM delivers real-time glucose information direct to the user’s iOS device3. The user (and any care partners i.e. family members/carers or healthcare professionals) can be alerted if they’re heading towards hypoglycaemia or hyperglycaemia.

This is important because people who are hypo unaware are six times more likely to have severe hypoglycaemia leading to seizures, coma and even death.[i] Having hypos leads to more hypos and the increased risk of these severe events.

WHAT THIS ANNOUNCEMENT MEANS TO LUCY CASSON

Lucy CassonLucy Casson is a Clinical Nurse Consultant in the Paediatric Endocrinology department at Sydney Children’s Hospital. Lucy works with patients and families who are impacted by diabetes. Lucy shares her thoughts on the decision:

“I cried when I heard the news. The decision to fund CGM for paediatric patients will be life changing for paediatric patients – but mainly for their parents. Ask any parent of a child with T1D what their main worry is and it is likely to be hypoglycaemic events during the night. This technology will notify them of a high or low glucose level and they can manage it appropriately. Some parents will be able to sleep through the night for the first time in years.

I firmly believe funding should be available to anyone who is on insulin, and there is an opportunity to reduce hospital admissions for young adults. Young adults who live on their own face a dangerous risk. A hypoglycaemic or hyperglycaemic event may be detected the next day and presentation at an Emergency department is required. There are opportunities to improve outcomes for this group of patients – and all patients with Type 1 and Type 2 diabetes.

I understand that they had to start somewhere and this is literally life changing. This will change the lives of families across Australia.”

LEARN MORE

To learn more about the subsidised CGM Initiative, please call your local Medtronic Diabetes representative, visit the NDSS website, contact us here or read our Frequently Asked Questions.


[i] Prevalence of impaired awareness of hypoglycaemia in adults with Type 1 diabetes. Geddes J, Schopman JE, Zammitt NN, Frier BM. Diabet Med. 2008 Apr; 25(4):501-4. 1 Effect of Sensor-Augmented Insulin Pump Therapy and Automated Insulin Suspension vs Standard Insulin Pump  Therapy on Hypoglycaemia in Patients With Type 1 Diabetes. A Randomized Clinical Trial. Ly T.T. et al.  JAMA 310(12):1240-1247, 2013. 2 Hypoglycemia Prevention and User Acceptance of an Insulin Pump System with Predictive Low Glucose Management. Choudhary et al. DIABETES TECHNOLOGY & THERAPEUTICS Vol 18. No 5, 2016. 3 The Guardian Connect app is compatible with iOS9 and above. The app will be compatible with the following hardware devices: iPhone 4S iPhone 5 iPhone 5C iPhone 5S iPhone 6 iPhone 6 Plus iPhone 6S iPhone 6S Plus iPhone SE iPod Touch (5th generation) iPod Touch (6th generation) iPad 3 iPad 4 iPad Air iPad Air 2 iPad Pro iPad Mini iPad Mini 2 iPad Mini 3 iPad Mini 4. Guardian Connect data cannot be transmitted via a MiniMed Insulin pump.